Tools for research

Essential Reagents for COVID-19(SARS-CoV-2) IgM/IgG Rapid Test Development

Elabscience^® provides essential reagents for development of COVID-19 IgG/IgM Lateral Flow (Rapid Test) assay to help with the qualitative detection of IgG and IgM antibodies specific to SARS-CoV-2 in human biological fluids.

SARS-CoV-2 Host Associated Proteins

Coronaviruses have four structural proteins (E,M,N,S protein) that can bind to membrane receptors on host cells, thereby mediating the fusion of the virus and the cell membrane. After the S protein of SARS-CoV-2 interacts with ACE2 and then enters the cell through endocytosis, Cathepsin B/L degrades the Spike protein to release nucleic acids of virus. In addition, CD147 also plays a functional role in promoting SARS-CoV-2 invasion into host cells.

ELISA Kits for SARS-CoV-2 Antigen/Antibody Detection

Elabscience^® newly developed ELISA kits for SARS-CoV-2 antigen/antibody determination. These kits are mainly specific to the most important structural proteins, the spike protein and nucleocapsid protein.

ELISA Kits for Monitoring the Cytokine Storm

Accumulating research evidence indicates that many patients with severe COVID-19 might have a cytokine storm syndrome, and this suggests that people with severe COVID-19 or suspicious COVID-19 infection should be monitored for hyperinflammation.

SARS-CoV-2(2019-nCoV) Antibodies

Since the SARS-CoV-2-Spike protein and Nucleocapsid Protein (NP) are the biomarkers of 2019-nCoV, and angiotensin convertenzyme 2 (ACE-2) is the main surface receptor to SARS-CoV-2 , it is important to fully understand the role these proteins play in SARS-CoV-2 infection. Elabsicnece^® offers a variety of antibodies to investigate the mechanisms of the SARS-CoV-2 life cycle.

Cell Line for the Research of SARS-CoV-2

Current events around the spread of COVID-19 (SARS-CoV-2) and its impact on public health continue to evolve. Researchers all over the world are committed to the development of COVID-19 vaccine and the development of drugs. In vitro experiments using cell lines for drug screening can greatly improve the speed of screening anti-SARS-CoV-2 drugs.

References

1. Zhang, Y.-Z. & Holmes, E. C. A Genomic Perspective on the Origin and Emergence of SARS-CoV-2. Cell 0, (2020)

2. Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell (2020)

3. Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 1–12 (2020)

4. Lan, J. et al. Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. Nature 1–20 (2020)

5. Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 1–8 (2020)

6. Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020)

7. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020)

8. Lam, T. T.-Y. et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature 1–6 (2020)

9. Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020)

10. Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. (2020)

11. Xu, Y. et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat. Med. 1–4 (2020)

12. Yan, R. et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science (2020)